Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Hereditary Breast and Ovarian Cancer KNOWING WHAT TO LOOK FOR KNOWING WHERE TO LOOK AND KNOWING WHAT IT MEANS Breast and ovarian cancer occurs when normal cells in the breast or the ovary begin to grow uncontrollably, forming a malignant tumor. Breast cancer is the most common cancer in women, and 1 out of every 8 (12%) women will be diagnosed with breast cancer in their lifetime. Although the disease occurs more frequently in women, breast cancer can also occur in men. Ovarian cancer is the ninth most common cancer among females, occurring in 1 out of every 70 women. While the majority of breast and ovarian cancer is sporadic (non-hereditary), approximately 10% of all breast cancer and 25% of all ovarian cancers occur because an individual was born with a harmful change in a gene that increased their risk to develop cancer. These harmful changes are also known as pathogenic variants and can be identified through genetic testing. Genes and Lifetime Risks Many genes have been associated with an increased risk of breast and ovarian cancer. These genes can be categorized into three main groups: High-Risk, Moderate-Risk and Newer-Risk. Table 1 reviews the genes associated with an increased risk of breast and/or ovarian cancer in the presence of a pathogenic variant and provides information on other cancers and/or tumors associated with these genes. Specific lifetime risk estimates are provided when available and are based on published medical literature. GUIDE FOR HEREDITARY BREAST & OVARIAN CANCER 1 CLINICAL INFORMATION Hereditary Breast and Ovarian Cancer High-Risk Genes Moderate-Risk Genes Newer-Risk Genes CLINICAL INFORMATION Table 1: Lifetime Cancer and/or Tumor Risks for Genes Associated with Hereditary Breast and Ovarian Cancer Gene Lifetime Cancer and/or Tumor Risks* BRCA11,2 Female breast (57-87%), Ovarian (24-54%), Prostate, Male breast, Pancreatic, Fallopian tube, Primary peritoneal, Endometrial BRCA2 1,3 Female breast (41-84%), Prostate (20-34%), Ovarian (11-27%), Pancreatic (5-7%), Male breast (4-7%), Melanoma, Fallopian tube, Primary peritoneal, Endometrial CDH11 Gastric cancer (40-83%), Female breast (39-52%), Colon EPCAM, MLH1, MSH2, MSH6, PMS2 1 Colorectal (11-80%), Endometrial (12-61%), Ovarian (1-24%), Gastric (<1-20%), Urinary tract (1-10%), Pancreatic, Biliary tract, Small bowel, Brain, Sebaceous tumors PALB2 1,4 Female breast (25-58%), Male breast, Pancreatic, Ovarian PTEN 1,5 Female breast (25-85%), Thyroid (3-38%), Endometrial (5-28%), Colon, Renal, Melanoma, Gastrointestinal polyps TP53 Female breast, Sarcoma-bone and soft tissue, Brain, Hematologic malignancies, Adrenocortical carcinoma, among others. Overall risk for cancer: nearly 100% in females, 73% in males 1 Tumor spectrum is representative of Lynch syndrome; data are limited with regard to the association of certain cancers with pathogenic variants in MSH6, PMS2 and EPCAM Female breast, Colon, Pancreatic ATM 1 BRIP1 Ovarian, Female breast CHEK2 1,7 Female breast, Male breast, Colon, Prostate, Thyroid, Endometrial, Ovarian RAD51C 1,8 Ovarian, Female breast RAD51D 1,9 Ovarian, Female breast BARD110,11 Female breast, Ovarian FANCC 12 Female breast NBN 13 Female breast, Melanoma, Non-Hodgkin lymphoma XRCC2 14 Female breast, Pancreatic 1,6 *Lifetime risks are provided when available. Risks relate to carriers of a single pathogenic variant. 2 High-Risk Genes High-risk genes are well-studied, and pathogenic variants in these genes are associated with a significantly increased risk (greater than 4-fold risk when compared with the general population) to develop one or more cancers. These genes are often associated with well-defined hereditary cancer syndromes, which generally have published guidelines for screening and prevention. Patients with pathogenic variants in these genes may develop cancer and/ or tumors at young ages or may have an increased risk for multiple cancer diagnoses in a lifetime. High-risk genes associated with an increased risk of breast and/ or ovarian cancer include BRCA1, BRCA2 (BRCA-Related Breast and/or Ovarian Cancer syndrome); CDH1 (Hereditary Diffuse Gastric Cancer syndrome); EPCAM, MLH1, MSH2, MSH6, PMS2 (Lynch syndrome); PALB2; PTEN (PTEN Hamartoma Tumor syndrome, including Cowden syndrome); and TP53 (Li-Fraumeni syndrome). Figure 1 provides the lifetime breast and/or ovarian cancer risks when a pathogenic variant is identified in these high-risk genes. Figure 1: Lifetime Risk of Breast and Ovarian Cancer Associated with Pathogenic Variants in High-Risk Genes Female Breast Cancer* 100 Ovarian Cancer 90 54-87% 25-85% 41-84% 80 Range of Reported Risk increased** Cancer Risk (%) 70 60 50 25-58% 24-54% 39-52% 40 11-27% 30 1-24% 20 12% 10 0 increased** BRCA1 BRCA2 CDH1 EPCAM, PALB2 MLH1, MSH2, MSH6, PMS2 1-2% PTEN TP53 General Population High-Risk Genes * BRCA1, BRCA2, and PALB2 pathogenic variants are also associated with an increased risk for male breast cancer. ** Lifetime risks of cancer are known to be significantly increased for individuals with a pathogenic variant, although a precise lifetime risk is unknown. GUIDE FOR HEREDITARY BREAST & OVARIAN CANCER 3 Moderate-Risk Genes Moderate-risk genes are often well-studied, and pathogenic variants in these genes are associated with a more modest risk (approximately a 2- to 4-fold risk when compared with the general population) to develop one or more cancers. Generally, there are limited guidelines for screening and surveillance. Similar to highrisk genes, patients with pathogenic variants in these genes may develop cancer at an early age and may develop multiple cancer diagnoses in a lifetime. Newer-Risk Genes In addition to high-risk and moderate-risk genes, other genes have been identified that are not as well-studied. Often the association with cancer may be newly discovered, or there may be limited data on the degree of cancer risk and/or full spectrum of tumors associated with genetic variants in these genes. Guidelines for screening and prevention are limited or not available. 4 Identifying Patients at Risk for Hereditary Breast and Ovarian Cancer Individuals with a personal and/or family history of the following may be at risk for hereditary breast and ovarian cancer. Family history includes first, second, and third-degree blood relatives (including parents, siblings, children, aunts/uncles, cousins, and grandparents). GUIDE FOR HEREDITARY BREAST & OVARIAN CANCER 5 TEST INFORMATION It is important to provide detailed information on the personal and family histories of cancer, including ages of diagnosis, pathology, and relationship between family members. This information can help determine if testing is appropriate and which test is medically necessary, as well as may impact insurance coverage. TEST INFORMATION • Breast cancer diagnosed under 50 years of age • Multiple cancers in one person, either of the same origin (such as two separate breast cancers) or of different origins (such as breast cancer and ovarian cancer) • Ovarian cancer or male breast cancer at any age • Multiple relatives diagnosed with the same or related cancers (including breast, ovarian, pancreatic and/or prostate) on the same side of the family and spanning multiple generations • Ashkenazi Jewish ancestry with a history of breast, ovarian or pancreatic cancer • A known pathogenic variant in a blood relative Test Options TEST INFORMATION Below are the tests available for individuals at risk for hereditary breast and ovarian cancer. Test Name Genes Included Turn Around Time BRCA1/BRCA2 Sequencing and Deletion Duplication Analysis* BRCA1, BRCA2 8-10 days Breast Cancer High/Moderate Risk Panel (8 genes) ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, TP53 2 weeks Breast/Ovarian Cancer Panel (20 genes) ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, FANCC, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, PTEN, RAD51C, RAD51D, TP53, XRCC2 3 weeks High/Moderate Risk Panel (23 genes) APC, ATM, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDKN2A, CHEK2, EPCAM, MLH1, MSH2, MSH6, MUTYH, PALB2, PMS2, PTEN, RAD51C, RAD51D, SMAD4, STK11, TP53, VHL 3 weeks Comprehensive Cancer Panel (32 genes) APC, ATM, AXIN2, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, FANCC, MLH1, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, POLD1, POLE, PTEN, RAD51C, RAD51D, SCG5/GREM1, SMAD4, STK11, TP53, VHL, XRCC2 3 weeks OncoGeneDx Custom Panel (up to 61 genes) ALK, APC, ATM, AXIN2, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDC73, CDH1, CDK4, CDKN2A, CHEK2, DICER1, EPCAM, FANCC, FH, FLCN, MAX, MEN1, MET, MITF, MLH1, MSH2, MSH6, MUTYH, NBN, NF1, NF2, PALB2, PHOX2B, PMS2, POLD1, POLE, PRKAR1A, PTCH1, PTEN, RAD51C, RAD51D, RB1, RET, SCG5/GREM1, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, STK11, SUFU, TMEM127, TP53, TSC1, TSC2, VHL, WT1, XRCC2 3 weeks *Targeted testing for the three common pathogenic variants found in the Ashkenazi Jewish population is also available 6 Additional testing options are available, including targeted variant testing for a previously identified pathogenic or likely pathogenic variant in a family member. Appropriate test selection depends on the specific clinical history of a patient, including family history of cancer and/or previous personal or familial test results. Testing for most genes includes sequencing and deletion/duplication analysis via next-generation sequencing and/or exon array testing. Sample Submission Genetic testing can be performed on blood, oral rinse or extracted DNA samples. GeneDx test kits are available to ordering providers, and include sample collection items (such as mouthwash for oral rinse and collection tubes), the necessary sample submission paperwork, and a self-addressed return shipping label. Additionally, all test requisition forms are available for download from the GeneDx website: www.genedx.com/forms Please note that all testing must be performed under the guidance of a healthcare provider. For more information on the sample submission process, please visit our website: www.genedx.com/supplies or email us at: [email protected] GUIDE FOR HEREDITARY BREAST & OVARIAN CANCER 7 Genetic Testing Process Patient Identification Sample Submission Discussion of personal and family history The patient’s sample and necessary paperwork are sent to the laboratory Explanation of genetic testing options Genetic Testing At the laboratory, genetic testing for most genes includes next-generation sequencing and/or exon array analysis Genetic Test Results Final Report BRCA1/2 Breast/Ovarian Cancer Panel Negative PHYSI g and Deletion/D Sequencin CIAN Center Information for Individuals Who Have Tested Negative for Pathogenic Variants Dr. XYZ Oncology NEGATIVE Report Analysis Genetic Test uplication Oncology Contains information on the results of the genetic test and available medical management options PATIE NT Sample Patient Age: 28 Sex: DOB: 02/21/1983 111111 Patient ID: Specimen What This Test Result Means For You: Additional Healthcare Provider: uplication ng and Deletion/D SAMPL E ID: 111111111 Date of Report: F 4/29/2016 4/20/2016 Date Collected: 4/22/2016 Date Received: IN EDTA Source: BLOOD Address: ST St 555 Main 123 MAIN NJ 12345 NJ , Anytown, ANYTOWN You have undergone genetic testing for genes associated with an increased M1 risk for breast and/or ovarian Your test was negative for 90cancer.12345 X1111 any pathogenic (harmful) variants. 90 F: 123-456-78 P: 123-456-78 Test Results: Analysis If you have been diagnosed with cancer, the reason why you developed cancer remains unknown. It is possible that you have a Sequenci cancer. BRCA2 pathogenic variant in an untested area of the genes analyzed or youBRCA1/2 have a pathogenic variant in an unidentified gene. It is also possible of breast BRCA1, Evaluated: that your cancer was caused by factors other than your genes. You should your medical management as recommended Family by your history Genes continue l cancer. doctor. id endometria Test Indication endometrio of If you have never been diagnosed with cancer or symptoms associated with onehistory of the genes/syndromes on this panel, and have undergone testing based on a family history of cancer with no known Personal pathogenic variant in the family, this result does not provide an Zygosity explanation for the cancer in your family. Your risk to develop cancer may still be increased and you should continue with medical GOUS management based on your medical and/or family history. Your result may be negative because there is a genetic predisposition in your HETEROZY ion Classificat or BRCA2. family that you did not inherit or it may be that the cancer in your family is caused by something beyond the genes included in this test. : POSITIVE of BRCA1 Summary To clarify which of these explanations is more likely, it may be helpful to test a member of your family who has been diagnosed withPATHOGENIC Results plication analysis Results cancer in order to determine if the cause of the cancer in your family can be identified. Testing other family members ) may also help to or deletion/du (p.Cys61Gly clarify your risk of developing cancer. Gene by sequencing c.181T>G For Your Family: BRCA1 No additional reportable variants were detected Although testing was negative, your family members may still be at increased risk for developing cancer. If a genetic cause for the cancer in you and/or your family has not been identified, genetic testing for family members who have not been diagnosed with cancer may not be useful. In some cases, it may be helpful for other relatives with a cancer diagnosis to undergo this testing, particularly if diagnosed at a young age or with a less common type of cancer such as ovarian cancer. Share a copy of your test report with your biologic family members, so that their doctors knows which genes were tested. Clinical Summary The final report is sent to the ordering healthcare provider for a pathogenic Ovarian Breast and women with Hereditary breast cancer in for BRCA1, consistent to 87% risk variant in with a 57% associated clinical summary. are If your family members would like to learn more about their risk for developing cancer, genetic counseling us is recommended. The National in BRCA1 n for detailed is heterozygo variants Society of Genetic Counselors maintains a list of national and internationalThis genetic counselors. Visit www.nsgc.org to locate a genetic individual interpretatio Pathogenic cancer. See counselor near you. syndrome. for ovarian Cancer to 54% risk and a 24% nt of these results. manageme the implications Ovarian include ed to discuss t: Breast and in the current variant identified Guidelines Breast the pathogenic family members. also having for this individual’s • The NCCN ations for Hereditary . chance of counselors recommend is available up to a 50% our genetic Glossary or relatives have for pathogenic variants call one of genetic variant detail, please • First degreeTargeted testing with the same in further Gene: A defined segment of DNA that provides instructions for the cells of the bodyindividual. to make a specific protein. and families please visit these results to discuss more, Genetic: Refers to a medical condition that is caused, at least in part, by an alteration (or pathogenic in a person’s DNA. Genetic likevariant) enable individuals created to d information. To learn conditions are often inherited, or passed down through the family tree. • If you would ticNIH initiative brca2-gene Pathogenic Variant: An alteration in DNA considered to increase the risk for or cause the development particular disease. de-identifie nnectofisa an /brca1-andand share enedx.com • GenomeCo to connect www.oncog rg. visit: medical history econnect.o Patient Resources results, please www.genom about these • Facing Our Risk Of Cancer Empowered (FORCE): www.facingourrisk.org more information • Bright Pink: www.brightpink.org • To learn itive-results • National Cancer Institute: www.cancer.gov/cancertopics/genetics testing-pos • GeneDx: www.oncogenedx.com Medical Management Options ndations Recomme There are a variety of management strategies available to individuals at an increased risk to develop breast and/or ovarian cancer based is recommend Assessmen counseling on genetic test results and/or personal or family history risk factors. Medical management and you should syndrome. milial High-Risk • Genetic varies for each patient, for Genetic/Fa and Ovarian Cancer discuss your specific options with your doctor. Page 1 of 4 Signed By: Report Electronically MS, CGC Kristin Theobald, Genetic Counselor Signed By: F: (301) 710-6594 FACMG Inc. Report Electronically P: (888) 729-1206 MBBS, PhD, Laboratories, MD 20877 Ying Wang, Geneticist Gaithersburg, unit of BioReference a business Clinical Molecular Perry Parkway, GeneDx is GeneDx 207 Ph.D., FACMG Anne Maddalena, Director Laboratory ology genedx.com/onc © 2016 GeneDX. All rights reserved. 91459 6/2016 Information current as of 6/2016 Post-Test Discussion Healthcare provider discusses the test results, medical management options, and implications for family members with the patient 8 Genetic Test Results Nearly all test results fall into one of four categories: positive (pathogenic variant), likely pathogenic variant, negative and a variant of uncertain significance (VUS). Genetic counseling is recommended prior to and following genetic testing to understand the benefits and limitations of testing. Final Report Positive Result Oncology Genetic Test Report BRCA1/2 Sequencing and Deletion/Duplication Analysis PHYSICIAN A positive result indicates a genetic variant (change) was identified in a specific gene that is pathogenic (harmful). With a positive test result, the risk to develop a particular disease (in this case, cancer and/or tumors) is increased. The lifetime risk for cancer and/or tumors depends on which gene was identified as having the pathogenic variant. Dr. XYZ Oncology Center 123 MAIN ST ANYTOWN, NJ 12345 X1111 M1 P: 123-456-7890 F: 123-456-7890 PATIENT Sample Patient DOB: 02/21/1983 Age: 28 Sex: F Patient ID: 111111 Address: 555 Main St Anytown, NJ 12345 SAMPLE Specimen ID: 111111111 Date of Report: 4/29/2016 Date Collected: 4/20/2016 Date Received: 4/22/2016 Source: BLOOD IN EDTA Additional Healthcare Provider: BRCA1/2 Sequencing and Deletion/Duplication Analysis Genes Evaluated: BRCA1, BRCA2 Test Indication Personal history of endometrioid endometrial cancer. Family history of breast cancer. Results Summary: POSITIVE Gene BRCA1 Results c.181T>G (p.Cys61Gly) Classification Zygosity PATHOGENIC HETEROZYGOUS No additional reportable variants were detected by sequencing or deletion/duplication analysis of BRCA1 or BRCA2. Clinical Summary This individual is heterozygous for a pathogenic variant in BRCA1, consistent with Hereditary Breast and Ovarian Cancer syndrome. Pathogenic variants in BRCA1 are associated with a 57% to 87% risk for breast cancer in women and a 24% to 54% risk for ovarian cancer. See interpretation for detailed clinical summary. Recommendations • Genetic counseling is recommended to discuss the implications of these results. • The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian include management recommendations for Hereditary Breast and Ovarian Cancer syndrome. • First degree relatives have up to a 50% chance of also having the pathogenic variant identified in the current individual. Targeted testing for pathogenic variants is available for this individual’s family members. • If you would like to discuss these results in further detail, please call one of our genetic counselors. • GenomeConnect is an NIH initiative created to enable individuals and families with the same genetic variant or medical history to connect and share de-identified information. To learn more, please visit www.genomeconnect.org. • To learn more information about these results, please visit: www.oncogenedx.com/brca1-and-brca2-genetictesting-positive-results Page 1 of 4 Report Electronically Signed By: Ying Wang, MBBS, PhD, FACMG Clinical Molecular Geneticist Anne Maddalena, Ph.D., FACMG Laboratory Director Report Electronically Signed By: Kristin Theobald, MS, CGC Genetic Counselor GeneDx 207 Perry Parkway, Gaithersburg, MD 20877 P: (888) 729-1206 F: (301) 710-6594 GeneDx is a business unit of BioReference Laboratories, Inc. genedx.com/oncology Likely Pathogenic Variant Result A likely pathogenic variant result indicates that there is a variant in a specific gene for which there is significant, but not conclusive, evidence that there is a risk to develop a particular disease (in this case, cancer and/or tumors). The lifetime risk for cancer and/or tumors depends on which gene was identified as having the likely pathogenic variant. With this type of result, a medical management plan may include similar options as described above for a positive result, including enhanced screening, risk-reducing options and testing of family members. GUIDE FOR HEREDITARY BREAST & OVARIAN CANCER 9 RESULTS / MANAGEMENT Knowledge of a positive result provides valuable information to patients, healthcare providers, and family members as they develop a medical management plan to direct treatment of a current cancer diagnosis or reduce the risk for or improve early detection of future cancers and/or tumors. A medical management plan may include enhanced screening or in some cases, riskreducing surgery. Furthermore, testing family members may be appropriate and can allow for more accurate predictions of their cancer and/or tumor risks. Negative Result NEGATIVE A negative result means that no reportable variants were identified. This result can have different implications depending on the specific circumstances related to the testing. In many cases when no one in the family has previously been found to have a pathogenic variant, the reason for the patient’s personal or family history of cancer remains unknown. The result may be negative because there is a genetic predisposition in the family that the patient did not inherit or it may be that the cancers and/or tumors in the family are caused by something beyond the genes included on their test. The risk for future cancers and medical management recommendations should be based on personal and/or family history of cancer. Breast/Ovarian Cancer Panel Negative Information for Individuals Who Have Tested Negative for Pathogenic Variants Test Results: You have undergone genetic testing for genes associated with an increased risk for breast and/or ovarian cancer. Your test was negative for any pathogenic (harmful) variants. What This Test Result Means For You: If you have been diagnosed with cancer, the reason why you developed cancer remains unknown. It is possible that you have a pathogenic variant in an untested area of the genes analyzed or you have a pathogenic variant in an unidentified gene. It is also possible that your cancer was caused by factors other than your genes. You should continue your medical management as recommended by your doctor. If you have never been diagnosed with cancer or symptoms associated with one of the genes/syndromes on this panel, and have undergone testing based on a family history of cancer with no known pathogenic variant in the family, this result does not provide an explanation for the cancer in your family. Your risk to develop cancer may still be increased and you should continue with medical management based on your medical and/or family history. Your result may be negative because there is a genetic predisposition in your family that you did not inherit or it may be that the cancer in your family is caused by something beyond the genes included in this test. To clarify which of these explanations is more likely, it may be helpful to test a member of your family who has been diagnosed with cancer in order to determine if the cause of the cancer in your family can be identified. Testing other family members may also help to clarify your risk of developing cancer. For Your Family: Although testing was negative, your family members may still be at increased risk for developing cancer. If a genetic cause for the cancer in you and/or your family has not been identified, genetic testing for family members who have not been diagnosed with cancer may not be useful. In some cases, it may be helpful for other relatives with a cancer diagnosis to undergo this testing, particularly if diagnosed at a young age or with a less common type of cancer such as ovarian cancer. Share a copy of your test report with your biologic family members, so that their doctors knows which genes were tested. If your family members would like to learn more about their risk for developing cancer, genetic counseling is recommended. The National Society of Genetic Counselors maintains a list of national and international genetic counselors. Visit www.nsgc.org to locate a genetic counselor near you. Medical Management Options There are a variety of management strategies available to individuals at an increased risk to develop breast and/or ovarian cancer based on genetic test results and/or personal or family history risk factors. Medical management varies for each patient, and you should discuss your specific options with your doctor. Glossary Gene: A defined segment of DNA that provides instructions for the cells of the body to make a specific protein. Genetic: Refers to a medical condition that is caused, at least in part, by an alteration (or pathogenic variant) in a person’s DNA. Genetic conditions are often inherited, or passed down through the family tree. Pathogenic Variant: An alteration in DNA considered to increase the risk for or cause the development of a particular disease. Patient Resources • Facing Our Risk Of Cancer Empowered (FORCE): www.facingourrisk.org • Bright Pink: www.brightpink.org • National Cancer Institute: www.cancer.gov/cancertopics/genetics • GeneDx: www.oncogenedx.com RESULTS / MANAGEMENT © 2016 GeneDX. All rights reserved. 91459 6/2016 Information current as of 6/2016 When an individual tests negative for a familial pathogenic variant that has already been identified in another family member, this is considered a true negative test result. In most cases, the risk for cancer is not expected to be greater than the general population. Sometimes this interpretation may be limited if the family member’s pathogenic variant was identified in a gene described as moderate-risk or newer-risk. Depending upon the patient’s personal and family history of cancer, additional genetic testing may be indicated for the patient or a family member. Sometimes there are other genes that can explain the family history of cancer, or areas of a gene which were not examined with the initial test. A genetic specialist or other healthcare provider can determine if further genetic testing is appropriate. Variant of Uncertain Significance (VUS) Result A variant of uncertain significance (VUS) result means that a change in a specific gene was identified, however the effect of the variant cannot be clearly established. There may be conflicting or incomplete information in the medical literature about this variant 10 and its association with an increased risk of cancers and/or tumors is unknown. In other words, it cannot be determined yet whether this variant is associated with an increased risk of cancer and/ or tumors or it is a harmless (normal) variant. In some cases, it may be helpful to test other family members through our Variant Testing Program to help clarify the risk. Over time, the VUS may become reclassified to either a “positive” or “negative” test result. The patient’s risk for future cancers and medical management recommendations should typically be based on personal and/or family history until the VUS is reclassified. Test Reports Test reports contain detailed information about a specific genetic result and, if available, medical management options. Additional support is available from our laboratory genetic counselors and local genetic providers within your area. Genetic counseling services across the country can be found at: www.nsgc.org Test results are available within three weeks after a sample is received in the laboratory. Once complete, test results are sent to the ordering healthcare provider. The healthcare provider should share those results and discuss them in the context of the reported personal and family histories. Medical Management Based on Genetic Test Results Medical management options for early detection or risk reduction are available for many individuals found to have a pathogenic variant in a gene associated with hereditary cancer. The options may include enhanced screening, risk reducing surgery, and in some cases, risk reducing medication. Options for screening and risk reduction are based on national guidelines or consensus statements, when available, and are specific to the gene in which a pathogenic variant is identified. Information on screening and risk reduction options are included in the report for a positive and likely pathogenic test result. A summary of medical management options are provided in Table 2. GUIDE FOR HEREDITARY BREAST & OVARIAN CANCER 11 Table 2: Medical Management Options for Genes Associated with Hereditary Breast and Ovarian Cancer RESULTS / MANAGEMENT Gene Medical Management Guidelines ATM1 • • • • Increased breast awareness, including breast self-examination Clinical breast examination Breast MRI and mammogram starting at an early age Consider breast cancer risk-reduction strategies BRCA1, BRCA21 • Increased breast awareness, including breast self-examination for both men and women • Clinical breast examination for both men and women • Breast MRI and mammography starting at an early age • Consider prophylactic mastectomy • Bilateral salpingo-oophorectomy (BSO) • Consider transvaginal ultrasound of ovaries and CA-125 blood tests for women who have not had a BSO • Consider the use of risk-reducing medications (such as tamoxifen, raloxifene and oral contraceptives) • Consider prostate cancer screening starting at an early age • Consider pancreatic cancer screening and full body skin examination dependent on family history BRIP11 • Consider bilateral salpingo-oophorectomy CDH11,15 • • • • • • • • Increased breast awareness, including breast self-examination Clinical breast examination Breast MRI and mammography starting at an early age Consider prophylactic mastectomy Consider the use of risk-reducing medications (such as tamoxifen or raloxifene) Prophylactic gastrectomy In the absence of gastrectomy, upper endoscopy Consider colonoscopy beginning at an early age dependent on family history CHEK21,16 • • • • • Increased breast awareness, including breast self-examination Clinical breast examination Breast MRI and mammogram starting at an early age Consider breast cancer risk-reduction strategies Periodic colonoscopy starting at an early age* For all genes EPCAM MLH1 MSH2 MSH6 PMS216 • Frequent colonoscopy (every 1-2 years in many cases) starting at an early age • Consider the option of prophylactic colectomy, particularly if the patient requires surgery to address a colonic neoplasm or is not an optimal candidate for surveillance • Consider endometrial/ovarian cancer screening, which may include endometrial biopsy, transvaginal ultrasound and CA-125 blood tests • Consider prophylactic hysterectomy and salpingo-oophorectomy once a woman has completed childbearing For EPCAM, MLH1, MSH2 only • Consider upper endoscopy with extended duodenoscopy • Consider urinalysis to screen for urinary tract cancers • Consider physical examination with neurological examination 12 Gene PALB21,17 Medical Management Guidelines • • • • Increased breast awareness, including breast self-examination Clinical breast examination Breast MRI and mammogram starting at an early age Consider risk-reduction strategies, including the option of prophylactic mastectomy • Consider pancreatic cancer screening dependent on family history • • • • PTEN1 • • • • • • • Increased breast awareness, including breast self-examination Clinical breast examination Breast MRI and mammography starting at an early age Consider endometrial biopsy and/or transvaginal ultrasound starting at an early age; encourage patient education and prompt response to symptoms Options of prophylactic mastectomy and hysterectomy can be discussed Periodic colonoscopy starting at an early age Thyroid ultrasound Consider renal ultrasounds Physical examination Consider dermatological examination One or more management recommendations may begin in childhood or adolescence RAD51C1 • Consider bilateral salpingo-oophorectomy RAD51D1 • Consider bilateral salpingo-oophorectomy Increased breast awareness, including breast self-examination Clinical breast examination Breast MRI and mammography starting at an early age Consider prophylactic mastectomy Consider increased colonoscopy screening starting at an early age Consider whole body MRI, including brain imaging Comprehensive physical examination, including neurologic and skin examination starting at an early age • Use caution regarding radiation therapy for cancer • Additional surveillance based on family history of cancer • One or more management recommendations may begin in childhood or adolescence * Given limited data to support these guidelines, caution should be used when making recommendations. For the details on the specific medical management options, including frequency of screening and ages to begin surveillance, please review the referenced guidelines or consensus statements. GUIDE FOR HEREDITARY BREAST & OVARIAN CANCER 13 RESULTS / MANAGEMENT TP531 • • • • • • • Implications for Family Members Regardless of the result, patients should share their test report with their blood relatives, who can then discuss the results with their healthcare providers. Sharing a copy of the test result with family members and healthcare providers will help to determine if additional testing is necessary and will ensure that the proper test is ordered for relatives, if indicated. For most positive or likely pathogenic test results, first-degree relatives (including parents, siblings, and children) have a 50% chance to have the same variant. The risk for other family members to carry the variant depends on how closely related they are to the person with a positive or likely pathogenic test result. It is important to remember that for most of these genes, not all people who inherit a pathogenic or likely pathogenic variant will develop cancer and/or tumors, but the chance is increased above that of the general population. In some cases, certain genes may also be associated with an autosomal recessive condition. This occurs when an individual inherits two pathogenic variants, one from each parent. For most autosomal recessive conditions, the two pathogenic variants occur within the same gene and affect both copies of that gene. The genes associated with autosomal recessive conditions include ATM, BRCA2, BRIP1, FANCC, NBN, PALB2, RAD51C, XRCC2 and the Lynch syndrome genes (EPCAM, MLH1, MSH2, MSH6 and PMS2).18-22 When an individual has two variants in these genes, the cancer and/or tumor risks and the risks to family members are different than described above. In the case of a positive result, the report will provide additional information on the gene, inheritance and cancer and/or tumor risks. 14 Genetic Counseling Prior to genetic testing, patients should speak to their healthcare provider and/or a genetic specialist about their personal and family history of cancer, allowing for cancer risk assessment. Healthcare providers should discuss the benefits and limitations of testing, as well as possible test results. These conversations help to determine if the patient meets clinical criteria for testing, facilitates appropriate test ordering and ensures that the patient has provided informed consent for genetic testing. If a pathogenic variant has already been identified in a family member, testing of the specific variant is appropriate. If a pathogenic variant has never been identified, an affected family member with the highest likelihood for a positive result (such as having early-onset disease, bilateral disease or multiple primaries) is ideally the best person for initial testing within a family. If an affected family member is not available, testing of an unaffected family member can be considered, although a negative test result will not guarantee that the individual does not have an increased risk for cancer and/or tumors. Once a patient makes the decision to undergo testing, posttest genetic counseling is recommended to understand the implications of the results, including discussion of cancer risks and appropriate medical management based on both the test results and the patient’s medical and family histories. Genetic counseling services across the country can be found at: www.nsgc.org KEY INFORMATION GUIDE FOR HEREDITARY BREAST & OVARIAN CANCER 15 Insurance Coverage and Cost for Genetic Testing GeneDx accepts all commercial plans and is a Medicare provider. Additionally, GeneDx is a registered provider with several Medicaid plans. If a patient does not have health insurance or cannot afford to pay the cost of testing, GeneDx provides a financial assistance program to help ensure that all patients have access to medically necessary genetic testing. For more information on the paperwork that is required by some insurance carriers, as well as additional details on patient billing or our financial assistance program, please visit our website: www.genedx.com/billing Genetic Information Nondiscrimation Act The Genetic Information Nondiscrimination Act of 2008, also referred to as GINA, is a federal law that protects Americans from discrimination by health insurance companies and employers based on their genetic information. However, this law does not cover life insurance, disability insurance, or long-term care insurance. GINA’s employment protections do not extend to individuals in the U.S. military, federal employees, Veterans Health Administration and Indian Health Service. Some of these organizations may have internal policies to address genetic discrimination. For more information, please visit: http://genome.gov/10002328 KEY INFORMATION Resources for Patients Bright Pink: www.brightpink.org Colon Cancer Alliance for Research and Education for Lynch Syndrome (CCARE): www.fightlynch.org Facing Our Risk of Cancer Empowered (FORCE): www.facingourrisk.org GeneDx: www.oncogenedx.com National Cancer Institute: www.cancer.gov National Society of Genetic Counselors: www.nsgc.org 16 References 1. NCCN Guidelines. Genetic/Familial High-Risk Assessment: Breast and Ovarian. (URL: http://www.nccn.org/ professionals/physician_gls/f_guidelines.asp) [February 2016 accessed] 2. Ford D et al. Risks of cancer in BRCA1-mutation carriers. The Breast Cancer Linkage Consortium. Lancet. 1994 Mar;343(8899):692-5 3. Ford D et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998 Mar;62(3):676-89 4. Ding YC et al. Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States. Breast Cancer Res Treat. 2011 Apr;126(3):771-8 5. Tan et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res. 2012 Jan 15;18(2):400-7 6. Seal S et al. Truncating mutations in the Fanconi anemia J gene BRCA1 are low-penetrance breast cancer susceptibility alleles. Nat Genet. 2006 Nov;38(11):1239-41 7. Walsh T et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A. 2011 Nov 1;108(44):18032-7 8. Meindl A et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet. 2010 May;42(5):410-4 9. Osher DJ et al. Mutation analysis of RAD51D in non-BRCA1/2 ovarian and breast cancer families. Br J Cancer. 2012 Apr 10;106(8):1460-3 10. Ratajska M et al. Cancer predisposing BARD1 mutations in breast-ovarian cancer families. Breast Cancer Res Treat. 2012 Jan;131(1):89-97 11. Pennington KP et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014 Feb 1;20(3):764-75 12. Thompson ER et al. Exome sequencing identifies rare deleterious mutations in DNA repair genes FANCC and BLM as potential breast cancer susceptibility alleles. PLoS Genet. 2012 Sep;8(9):e1002894. doi: 10.1371/ journal.pgen.1002894. Epub 2012 Sep 27 13. Steffen J et al. Germline mutations 657del5 of the NBS1 gene contribute significantly to the incidence of breast cancer in Central Poland. Int J Cancer. 2006 Jul 15;119(2):472-5 14. Park DJ et al. Rare mutations in XRCC2 increase the risk of breast cancer. Am J Hum Genet. 2012 Apr 6;90(4):734-9 15. NCCN Guidelines. Gastric Cancer. (URL:https://www.nccn.org/professionals/physician_gls/pdf/ gastric.pdf) [March 2016 accessed] 16. NCCN Guidelines. Genetic/Familial High-Risk Assessment: Colorectal. (URL: http://www.nccn.org/professionals/ physician_gls/f_guidelines.asp) [June 2016 assessed] 17. Canto MI et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013 Mar;62(3):339-47 18. Gatti R. Ataxia-Telangiectasia. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Fong CT, Mefford HC, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2016. 1999 Mar 19 [updated 2010 Mar 11] 19. Alter BP and Kupfer G. Fanconi Anemia. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Fong CT, Mefford HC, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2016. 2002 Feb 14 [updated 2013 Feb 3] 20. Varon R, DemuthI and Digweed M. Nijmegen Breakage Syndrome. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Fong CT, Mefford HC, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2016. 1999 May 17 [updated 2014 May 8] 21. Shamseldin HE et al. Exome sequencing reveals a novel Fanconi group defined by XRCC2 mutation. J Med Genet. 2012 Mar;49(3):184-6 22. Wimmer et al. Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium ‘care for CMMRD’ (C4CMMRD). J Med Genet. 2014 Jun;51(6):355-65 Select references provided. For additional details, please visit www.genedx.com/oncology-genetics GUIDE FOR HEREDITARY BREAST & OVARIAN CANCER 17 About GeneDx GeneDx was founded in 2000 by two scientists from the National Institutes of Health (NIH) to address the needs of patients diagnosed with rare disorders and the clinicians treating these conditions. Today, GeneDx has grown into a global industry leader in genomics, having provided testing to patients and their families in over 55 countries. Led by its world-renowned whole exome sequencing program, and an unparalleled comprehensive genetic testing menu, GeneDx has a continued expertise in rare and ultra-rare disorders. Additionally, GeneDx also offers a number of other genetic testing services, including: diagnostic testing for hereditary cancers, cardiac, mitochondrial, and neurological disorders, prenatal diagnostics, and targeted variant testing. At GeneDx, our technical services are backed by our unmatched scientific expertise and our superior customer support. Our growing staff includes more than 30 geneticists and 100 genetic counselors specializing in clinical genetics, molecular genetics, metabolic genetics, and cytogenetics who are just a phone call or email away to assist you with your questions and testing needs. We invite you to visit our website: www.genedx.com to learn more about us. 207 Perry Parkway Gaithersburg, MD 20877 T 1 888 729 1206 (Toll-free), 1 301 519 2100 • F 1 201 421 2010 E [email protected] • www.genedx.com © 2016 GeneDx. All rights reserved. 40002 08/16 Information current as of 08/16